Abstract: The present invention relates to immunointeractive molecules and their use in therapeutics and diagnostics. More particularly, the present invention provides antibodies that bind to NYK/flk-1 receptors, in particular the extracellular domain.

Abstract: The present application describes nucleic acid encoding, and methods for preparing, an antibody comprising a linear VH—CH1—VH—CH1 heavy chain fragment associated with two light chains.

Abstract: The present invention provides an antibody which specifically reacts with an epitope of a polypeptide comprising the amino acid sequence X-Y-CYS GLN GLU GLU GLU CYS PRO ASP PRO TYR LEU CYS SER PRO VAL THR ASN ARG CYS GLU CYS THR PRO VAL LEU CYS ARG MET TYR CYS LYS PHE TRP ALA LYS ASP GLU LYS GLY CYS GLU ILE CYS LYS CYS GLU GLU LEU CYS GLN ASN GLN ASN CYS THR LYS ASP MET LEU CYS SER SER VAL THR ASN ARG CYS ASP CYS GLN ASP PHE LYS CYS PRO GLN SER TYR CYS-Z (SEQ. ID NO. 1) wherein X is MET or absent; Y is 0-28 amino acids of the sequence LYS MET CYS TRP ASN LYS GLY CYS PRO CYS GLY GLN ARG CYS ASN LEU HIS ARG ASN GLU CYS GLU VAL ILE ALA GLU ASN ILE GLU, (SEQ. ID NO. 2) with the proviso that if part of the sequence is present, it is a carboxy-terminal part of the sequence including the carboxy-terminal GLU and wherein Val may be preceded by Gly; and Z is absent or all or a part of the sequence Pro110-Lys156 shown in FIG. 7 (SEQ. ID NO.

Abstract: Disclosed is a method for enhancing an immune response against an antigen by topical administration of an antigen or a portion thereof in conjunction with an enhancer of skin penetration and an inducer of Langerhans cell migration.

Abstract: Disclosed is an antibody that binds to a protein found on normal and cancerous prostate cells, but not found on nonprostate cells and a hybridoma that produces the antibody to the prostate-specific protein. Also disclosed are antibodies conjugated to labels or cytotoxic moieties.

Abstract: Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

Abstract: A process for assaying for cancer of the prostate, comprising assaying a sample derived from a human for prostate specific antigen having a linked oligosaccharide which is at least triantennary. The assay may employ a binding molecule which binds to oligosaccharides that are at least triantennary, but does not bind to oligosaccharides that are monoantennary or diantennary. Such binding molecule may be a lectin such as PHA-L or an antibody to an oligosaccharide that is at least triantennary.

Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Abstract: DNA encoding TGF-&bgr; TYPE III receptor of mammalian origin, DNA encoding TGF-&bgr; type II receptor of mammalian origin, TGF-&bgr; type III receptor, TGF-&bgr; type II receptor and uses therefor.

Abstract: The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.

Abstract: A method and kit for measurement of a steroid by means of a competitive immunoassay, preferably a competitive enzyme immunoassay. The method and kit involve the use of a steroid analogue conjugated to a label. The steroids that are amenable to detection by the method and kit of the present invention include estradiol and progesterone. The method comprises the steps of: a. incubating a mixture of a test sample suspected of containing a given steroid, a solid phase coupled to an antibody specific for that steroid, and a conjugate of an analogue of that steroid to form steroid/antibody complexes and conjugate/antibody complexes on said solid phase; b. separating said solid phase from said mixture; c. measuring the amount of label present in said mixture or in said solid phase; and d. determining the amount of steroid in said sample from the amount of label. The kit comprises a solid phase coupled to an antibody specific for a steroid and a conjugate of an analogue of that steroid.

Abstract: Measurements of elevated levels of riboflavin carrier protein (RCP) can be used to detect breast, liver, ovarian, and endometrial cancers. Stains for riboflavin carrier protein can be used to visualize malignancies in tissue specimens. The new technique is particularly well-suited for the early detection of breast cancer. With a radioimmunoassay for RCP, we have observed that serum RCP levels were significantly elevated in women with breast cancer as compared to control subjects. A serum RCP level ≧1.0 ng/ml was highly predictive of the presence of breast cancer (other than in pregnant females).

Abstract: The present invention relates to compositions of retinoids plus immunotoxins. More particularly this invention relates to the use of retinoids to potentiate the activity of immunotoxins for treatment of mammalian diseases.

Abstract: The invention relates to a labelled peptide compound, wherein the peptide has a selective neurotensin receptor affinity and is represented by the general formula R1—(1Pro)n—2Xaa—3Xbb—4Xcc—5Xdd—6Xee—7Leu—OH(SEQ ID NO.2)  (I) wherein: R1 is a (C1-C3)alkanoyl group, an arylcarbonyl group, an aryl-(C1-C3)alkanoyl group, or a chelating group attached by an amide bond or through a spacing group to the peptide molecule; Xaa and Xbb are each individually Arg or Lys; Xcc is an unsubstituted or substituted cyclic amino acid, preferably selected from Pro and Hyp; Xdd is Tyr, Trp or Phe; Xee is Leu, Ile or t.

Abstract: Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.

Abstract: The presence of A-protein in an abnormally large amount in a sample, such as blood, from an individual is diagnostic of primary or metastatic cancer in the individual. The presence of A-protein is most readily detected by immunological reaction of it with specific antibodies. A preferred procedure for detecting the presence of A-protein in samples is by a sandwich assay using two antibodies with different epitopic specificities for A-protein.

Abstract: The present invention relates to optionally substituted, non-toxic peptides and derivatives capable of inhibiting superoxide production in phagocytic cells. The invention also relates to compositions and methods useful in inhibiting inflammation and in treating inflammatory disorders such as autoimmune disorders, gout, adult respiratory distress syndrome, asthma, myocardial infarction, and various dermatological disorders. The present invention contemplates compositions derived from low molecular weight GTP-binding proteins (LMWG), mastoparan, GAP proteins, and related peptides. The invention further contemplates compositions useful in inhibiting activation of NADPH oxidase or in promoting GDP/GTP exchange. Therapeutic compositions containing various inhibitors, and methods of using same, are also disclosed.

Abstract: The invention provides a bcl-2 related protein, bcl-2 muteins, two-hybrid systems comprising interacting bcl-2-related polypeptide sequences, and uses thereof.

Abstract: A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

Abstract: The present invention provides methods of inhibiting angiogenesis by increasing the concentration of endostatin protein or endostatin protein fragments in vivo. The methods of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.